Table 4. CINV Prophylaxis Recommendations for Oral Chemotherapy.

Moderate to high emetic risk	Recommendation: Start 5-HT3 receptor antagonist before chemotherapy and continue daily
	Prophylaxis options: Dolasetron 100 mg po daily Granisetron 1–2 mg po daily Granisetron 3.1 mg/24-hr transdermal patch every 7 days Ondansetron 8–16 mg po daily
Minimal to low emetic risk	Recommendation: Provide patient with an as needed (prn) antiemetic agent; if CINV occurs, begin scheduled antiemetic before chemotherapy and continue daily.
	Prophylaxis options: Metoclopramide 10–20 mg po and then every 6 hr prn (maximum 40 mg/day) One of the 5-HT3 receptor antagonists: » Dolasetron 100 mg po daily prn » Granisetron 1–2 mg po daily prn » Ondansetron 8–16 mg po daily prn